DBV Technologies (NASDAQ:DBVT) Stock Price Crosses Above 50 Day Moving Average – Here’s Why

DBV Technologies S.A. (NASDAQ:DBVT)’s stock price passed above its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $8.89 and traded as high as $9.62. DBV Technologies shares last traded at $9.10, with a volume of 13,611 shares.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the company. Citigroup reissued an “outperform” rating on shares of DBV Technologies in a research note on Tuesday, May 27th. HC Wainwright increased their price target on shares of DBV Technologies from $7.00 to $16.00 and gave the company a “buy” rating in a research report on Monday, May 5th. Wall Street Zen upgraded shares of DBV Technologies from a “sell” rating to a “hold” rating in a report on Friday, May 9th. The Goldman Sachs Group raised shares of DBV Technologies to a “sell” rating and set a $7.25 target price for the company in a research note on Thursday, May 29th. Finally, JMP Securities increased their target price on shares of DBV Technologies from $15.00 to $21.00 and gave the stock a “market outperform” rating in a report on Tuesday, May 27th. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the stock. According to MarketBeat.com, DBV Technologies presently has a consensus rating of “Hold” and an average target price of $14.75.

DBV Technologies Stock Down 6.1%

The stock has a fifty day moving average of $8.89 and a 200-day moving average of $5.90. The firm has a market capitalization of $249.25 million, a P/E ratio of -2.02 and a beta of -0.63.

DBV Technologies (NASDAQ:DBVT) last issued its quarterly earnings results on Friday, April 11th. The company reported ($1.10) EPS for the quarter. The business had revenue of $0.51 million for the quarter. DBV Technologies had a negative return on equity of 106.07% and a negative net margin of 815.73%. Sell-side analysts predict that DBV Technologies S.A. will post -7.05 EPS for the current fiscal year.

Institutional Investors Weigh In On DBV Technologies

An institutional investor recently bought a new position in DBV Technologies stock. Boxer Capital Management LLC acquired a new position in shares of DBV Technologies S.A. (NASDAQ:DBVT) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 50,000 shares of the company’s stock, valued at approximately $154,000. Boxer Capital Management LLC owned about 0.24% of DBV Technologies as of its most recent SEC filing. 71.74% of the stock is owned by institutional investors.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.